Clinical Safety

Can Selenium Nanoparticles Revolutionize Precision Medicine?
Research & Development Can Selenium Nanoparticles Revolutionize Precision Medicine?

High-dose selenium can act as a specific inducer of ferroptosis in lung cancer cells, triggering a regulated, iron-dependent cell death that suppresses tumor growth. This discovery highlights the paradoxical nature of a trace element that is simultaneously indispensable and potentially lethal. For

Zolgensma Cancer Reports Put Long-Term Safety in Focus
Management & Regulatory Zolgensma Cancer Reports Put Long-Term Safety in Focus

Cancer reported in nine Zolgensma recipients is drawing fresh attention to a concern that gene therapy has faced for years. The FDA is investigating the cases, but says Zolgensma’s benefits still outweigh the possible risks when used as approved. For families and companies developing similar

Does Bone Marrow Sparing Improve Cervical Cancer Therapy?
Research & Development Does Bone Marrow Sparing Improve Cervical Cancer Therapy?

The persistent challenge of balancing aggressive oncologic treatment with the preservation of a patient's fundamental physiological resilience has led to a significant paradigm shift in the management of advanced cervical cancer. For decades, concurrent chemoradiotherapy has remained the standard

How Does Relational Safety Impact Ketamine-Assisted Therapy?
Management & Regulatory How Does Relational Safety Impact Ketamine-Assisted Therapy?

Clinicians face a heightened fiduciary obligation because ketamine temporarily impairs a patient’s ability to self-advocate or physically refuse treatment during the peak phase of its effects. This shift represents a radical departure from the conventional administration of SSRIs or other

New Clinical Process Developed for FAP-Targeting PET Tracers
Tech & Innovation New Clinical Process Developed for FAP-Targeting PET Tracers

To combat the risks of radiolysis during high-activity production runs, the final formulation of the tracer now includes a 10 milligram per milliliter concentration of ascorbic acid. This critical adjustment ensures that the molecular integrity of the tracer remains intact even when using higher

What Is the Future of JAK Inhibitors in Immune Disease Treatment?
Research & Development What Is the Future of JAK Inhibitors in Immune Disease Treatment?

Evidence from the RA-BEAM and SELECT-COMPARE trials indicates that certain JAK inhibitors can outperform tumor necrosis factor inhibitors in treating rheumatoid arthritis, a landmark finding that has accelerated the transition from traditional injectable biologics to oral small-molecule therapies.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later